Published in Cancer Treat Rev on June 01, 1982
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16
Prognosis and treatment of disseminated uveal melanoma. Cancer (1993) 1.98
MspA provides the main hydrophilic pathway through the cell wall of Mycobacterium smegmatis. Mol Microbiol (2001) 1.79
Eocene Patagonia fossils of the daisy family. Science (2010) 1.77
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol (2002) 1.68
Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) Ann Oncol (1997) 1.63
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol (2004) 1.59
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs (1996) 1.56
Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol (2001) 1.50
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol (1997) 1.46
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer (2006) 1.42
Energy transfer between fluorescent proteins using a co-expression system in Mycobacterium smegmatis. Gene (2001) 1.42
Novel tumor suppressor locus in human chromosome region 3p14.2. J Natl Cancer Inst (1999) 1.42
Unalarmed interruption of continuous drug infusion by Perfusor Space GC syringe pumps. Anaesthesia (2013) 1.39
D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res (2001) 1.38
Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol (1995) 1.36
Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia (1994) 1.32
Risk factors for venous thromboembolic events in cancer patients. Ann Oncol (2005) 1.32
Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol (1987) 1.25
Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs (2001) 1.23
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol (2005) 1.22
Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol (1999) 1.20
In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). Cancer Res (1982) 1.18
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol (1999) 1.17
Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet (1995) 1.17
Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients. Ann Oncol (2007) 1.16
Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer (1995) 1.16
[Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie (2010) 1.14
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer (2003) 1.12
Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol (1992) 1.12
Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther (2002) 1.11
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol (2006) 1.10
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. J Clin Oncol (1996) 1.09
Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clin Cancer Res (1998) 1.09
[Intra-operative drop in sevoflurane and oxygen concentrations. Leakage of the ventilation system]. Anaesthesist (2009) 1.08
A new dhfrVIII trimethoprim-resistance gene, flanked by IS26, whose product is remote from other dihydrofolate reductases in parsimony analysis. Gene (1995) 1.07
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Ann Oncol (2003) 1.07
[Chemotherapy in advanced sarcomas (author's transl)]. Dtsch Med Wochenschr (1981) 1.07
Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie (2010) 1.06
Duplication and functional divergence in the chalcone synthase gene family of Asteraceae: evolution with substrate change and catalytic simplification. Proc Natl Acad Sci U S A (1996) 1.05
Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol (1998) 1.05
Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer. Semin Oncol (1989) 1.05
Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. Cancer Res (2000) 1.04
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol (1999) 1.02
Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL). Br J Cancer (1977) 1.01
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol (2008) 1.01
Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. Cancer Immunol Immunother (1989) 0.99
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol (2005) 0.99
Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J Infus Chemother (1996) 0.98
Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia (2005) 0.98
Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol (1998) 0.98
Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer (1999) 0.97
Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors. Cancer Treat Rev (1982) 0.97
[On the enzyme therapy of leukemias]. Dtsch Med Wochenschr (1968) 0.97
Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol (1998) 0.96
Detection of chromosomal DNA gains and losses in testicular germ cell tumors by comparative genomic hybridization. Genes Chromosomes Cancer (1996) 0.96
[Chemotherapy of malignant bone tumors]. Chirurg (1977) 0.95
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. Clin Cancer Res (2001) 0.95
Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum II. J Cancer Res Clin Oncol (1980) 0.94
Letter: Chromosome abnormalities in angioimmunoblastic lymphadenopathy. Lancet (1976) 0.93
Enhancement of etoposide-induced cytotoxicity by cyclosporin A. Cancer Chemother Pharmacol (1986) 0.93
A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group. Eur J Cancer (1994) 0.93
[Lymphocyte in chronic lymphatic leukemia]. Blut (1975) 0.92
Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol (1999) 0.92
The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL). Z Krebsforsch Klin Onkol Cancer Res Clin Oncol (1976) 0.92
R factor elimination by inhibitors of thymidylate synthetase (fluorodeoxyuridine and showdomycin) and the occurrence of single strand breaks in plasmid DNA. Mol Gen Genet (1974) 0.91
Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking. Support Care Cancer (1994) 0.91
Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. Br J Cancer (1999) 0.91
Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol (1994) 0.91
Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol (1993) 0.91
[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie (2011) 0.91
DNA excision repair profiles of normal and leukemic human lymphocytes: functional analysis at the single-cell level. Cancer Res (1997) 0.90
Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res (2000) 0.90
Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the cervical oesophagus. Oncology (1999) 0.90
Fluorescence in-situ hybridization (FISH) reveals that in chronic myelogenous leukaemia (CML) following interferon-alpha therapy, normalization of megakaryocyte size is associated with the loss of bcr/abl translocation. Histopathology (1997) 0.89
Clonal growth of Hodgkin cells. Nature (1975) 0.89
Testosterone metabolism in human bone. Acta Endocrinol (Copenh) (1980) 0.89
Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. Acta Haematol (2006) 0.89
Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur J Cancer (1998) 0.89
Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res (1998) 0.89
Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management. Cancer (1994) 0.89
Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial. Br J Cancer (1999) 0.88
DNA sequence variations of the entire anti-Mullerian hormone (AMH) gene promoter and AMH protein expression in patients with the Mayer-Rokitanski-Kuster-Hauser syndrome. Hum Reprod (2004) 0.88